Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma

At the end of radiotherapy, 240mg of triplizumab was administered intravenously every cycle (21 days)

SBRT radiotherapy (radiotherapy dose: 40Gy, 5 times, 8Gy each time, number of metastatic radiotherapy: ≤5)